The specialty pharmacy will support access to VEPPANU, an FDA-approved PROTAC therapy for ESR1-mutated advanced or metastatic breast cancer after endocrine treatment progression.
Onco360 said Rigel Pharmaceuticals selected it as a pharmacy partner for VEPPANU (vepdegestrant), an FDA-approved treatment for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer identified by an FDA-authorized test after disease progression following at least one line of endocrine therapy. The company said the drug is a PROTAC (targeted protein-degradation therapy) that binds the estrogen receptor and E3 ligase cereblon, triggering degradation of the receptor protein in breast cancer cells. VEPPANU’s approval was based on the Phase 3 VERITAC-2 trial, where vepdegestrant reduced the risk of disease progression or death by 43% versus fulvestrant among patients with an ESR1 mutation. Onco360 Chief Commercial Officer Benito Fernandez said the partnership is aimed at accelerating patient access while providing clinical support and care throughout treatment.